Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide [Yahoo! Finance]
Skye Bioscience, Inc. (SKYE)
Company Research
Source: Yahoo! Finance
Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody. CBeyond Extension Study Design and Interim Data Summary The blinded extension of the CBeyond study for combination cohorts was opened in May 2025 for particip
Show less
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With SemaglutideGlobeNewswire
- Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity ConferenceGlobeNewswire
- Skye Bioscience to Present Poster at Keystone Obesity ConferenceGlobeNewswire
- Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law FirmGlobeNewswire
- Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYEPR Newswire
SKYE
Earnings
- 11/10/25 - Beat
SKYE
Analyst Actions
- 1/5/26 - Citigroup Inc.
SKYE
Sec Filings
- 2/2/26 - Form 8-K
- 12/23/25 - Form 8-K
- 12/16/25 - Form SCHEDULE
- SKYE's page on the SEC website